Loading...
Human Target Attainment Probabilities for Delafloxacin against Escherichia coli and Pseudomonas aeruginosa
BACKGROUND: Delafloxacin (DLX) is a broad-spectrum fluoroquinolone antibiotic under FDA review for the treatment of ABSSSI. Previous studies determined DLX bacterial stasis and 1-log(10) bacterial reduction free AUC(0-24) / MIC (fAUC(0-24)/MIC) targets for Escherichia coli (EC) and Pseudomonas aerug...
Na minha lista:
| Udgivet i: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5631342/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.1228 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|